Delivering high quality medications
developed specifically for
pediatric patients

Welcome to Silvergate

We are committed to making a difference in the lives of pediatric patients

At Silvergate, we are dedicated to improving the quality, accessibility, and delivery of FDA-approved medications for children. Learn more about why we’re taking the lead in this critical area.

Read More

Product News

FDA Approves Katerzia™, the First and Only Amlodipine Oral Suspension, 1 mg/mL, for Pediatric Patients 6 Years of Age and Older

WOBURN, Mass. (July 10, 2019) – Azurity Pharmaceuticals, a specialty pharmaceutical company that makes safe, high-quality treatments for patients requiring customized formulations for their care, announced today that the U.S. Food and Drug Administration (FDA) has approved Katerzia (amlodipine) Oral Suspension, 1 mg/mL, the first and only FDA-approved amlodipine oral suspension.

Xatmep – The First and Only Ready-To-Use Methotrexate Oral Solution is Now Available

Denver, July 31, 2017 — Silvergate Pharmaceuticals, Inc. (www.silvergatepharma.com), leaders in the development and commercialization of innovative and safe medicines for children, today announced that Xatmep™ (methotrexate) Oral Solution, the first and only FDA-approved methotrexate oral solution, is now available for ordering. Xatmep is indicated for the treatment of acute lymphoblastic leukemia (ALL) and the management of polyarticular juvenile idiopathic arthritis (pJIA) in pediatric patients.

EPANED® (enalapril maleate) Oral Solution 1 mg/mL, the First and Only FDA-Approved Enalapril Oral Solution for the Treatment of Pediatric Hypertension in Patients Older than 1 Month, is Now Available

Denver, January 10, 2017 — Silvergate Pharmaceuticals, Inc. (www.silvergatepharma.com), leader in the development and commercialization of innovative and safe medicines for children, today announced that EPANED® Oral Solution, the first and only FDA-approved enalapril oral solution, is now available for ordering.

Qbrelis™, the First and Only Lisinopril Oral Solution 1 mg/mL for Pediatric Patients 6 Years of Age and Older, is Now Available

Denver, October 26, 2016 — Silvergate Pharmaceuticals, Inc. (www.silvergatepharma.com), leader in the development and commercialization of innovative and safe medicines for children, today announced that Qbrelis™ (lisinopril) oral solution, the first and only FDA-approved lisinopril oral solution, is now available for ordering. Qbrelis™ is indicated for the treatment of hypertension (high blood pressure) in adult patients and pediatric patients 6 years of age and older, adjunct therapy for heart failure, and treatment of acute myocardial infarction (heart attack) in adults.

FDA Approves Qbrelis™, the First and Only Lisinopril Oral Solution 1 mg/mL for Pediatric Patients 6 Years of Age and Older

Denver, July 29, 2016 — Silvergate Pharmaceuticals, Inc. (www.silvergatepharma.com), leader in the development and commercialization of innovative and safe medicines for children, today announced that the United States Food and Drug Administration (FDA) approved Qbrelis™ (Lisinopril) Oral Solution, the first and only FDA-approved Lisinopril oral solution. Qbrelis™ is indicated for the treatment of hypertension (high blood pressure) in adult patients and pediatric patients 6 years of age and older, adjunct therapy for heart failure, and treatment of acute myocardial infarction in adults.

FDA Approves 2 New Indications for Epaned®, the First and Only Enalapril Powder for Oral Solution

Denver, September 8, 2014—Silvergate Pharmaceuticals, Inc. (www.Silvergatepharma.com), focused on the development and commercialization of innovative and safe medicines for children, today announced that the United States Food and Drug Administration (FDA) approved Epaned® (Enalapril Maleate Powder for Oral Solution) for the treatment of symptomatic heart failure and the treatment of asymptomatic left ventricular dysfunction (to decrease the rate of development of overt heart failure and to reduce hospitalization for heart failure). These indications are in addition to the prior approval for hypertension (high blood pressure) in patients older than 1 month.

FDA Approves Epaned, a Powder for a Liquid Form of Enalapril for Children and Adults

Denver, 13 August 2013— Silvergate Pharmaceuticals Inc, focused on the development and commercialization of innovative and safe medicines for children, today announced that the United States Food and Drug Administration (FDA) approved Epaned™ (enalapril maleate Powder for Oral Solution) to treat hypertension (high blood pressure) in people one month and older. Enalapril is one of the most commonly prescribed medicines in the United States to treat high blood pressure.

Featured Product

Xatmep – The First and Only Ready-To-Use Methotrexate Oral Solution is Now Available

Denver, July 31, 2017 — Silvergate Pharmaceuticals, Inc. (www.silvergatepharma.com), leaders in the development and commercialization of innovative and safe medicines for children, today announced that Xatmep™ (methotrexate) Oral Solution, the first and only FDA-approved methotrexate oral solution, is now available for ordering. Xatmep is indicated for the treatment of acute lymphoblastic leukemia (ALL) and the management of polyarticular juvenile idiopathic arthritis (pJIA) in pediatric patients.